- 1 International Multicenter Study Comparing Cancer to Non-Cancer Patients with COVID-
- 2 19: Impact of Risk Factors and Treatment Modalities on Survivorship
- 3 Issam Raad\*<sup>1</sup>, Ray Hachem\*<sup>1</sup>, Nigo Masayuki<sup>2</sup>, Tarcila Datoguia<sup>3</sup>, Hiba Dagher<sup>1</sup>, Ying Jiang<sup>1</sup>,
- 4 Vivek Subbiah<sup>4-5</sup>, Bilal Siddiqui<sup>6</sup>, Arnaud Bayle<sup>7</sup>, Robert Somer<sup>8</sup>, Ana Fernández Cruz<sup>9</sup>,
- 5 Edward Gorak<sup>10</sup>, Arvinder Bhinder<sup>11</sup>, Nobuyoshi Mori<sup>12</sup>, Nelson Hamerschlak<sup>3</sup>, Samuel
- 6 Shelanski<sup>13</sup>, Tomislav Dragivich<sup>14</sup>, Yee Elise Vong Kiat<sup>15</sup>, Suha Fakhreddine<sup>16</sup>, Pierre Abi
- 7 Hanna<sup>16</sup>, Roy F. Chemaly<sup>1</sup>, Victor Mulanovich<sup>1</sup>, Javier Adachi<sup>1</sup>, Jovan Borjan<sup>1</sup>, Fareed
- 8 Khawaja<sup>1</sup>, Bruno Granwehr<sup>1</sup>, Teny John<sup>1</sup>, Eduardo Yepez Guevara<sup>1</sup>, Harrys Torres<sup>1</sup>,
- 9 Natraj Reddy Ammakkanavar<sup>4</sup>, Marcel Yibirin<sup>1</sup>, Cielito C Reyes-Gibby<sup>17</sup>, Mala Pande<sup>18</sup>, Noman
- Ali<sup>19</sup>, Raniv Dawey Rojo<sup>20</sup>, Shahnoor M Ali<sup>1</sup>, Rita E Deeba<sup>1</sup>, Patrick Chaftari<sup>17</sup>, Takahiro
- 11 Matsuo<sup>12</sup>, Kazuhiro Ishikawa<sup>12</sup>, Ryo Hasegawa<sup>12</sup>, Ramón Aguado-Noya<sup>21</sup>, Álvaro García-
- 12 García<sup>22</sup>, Cristina Traseira Puchol<sup>21</sup>, Dong-Gun Lee<sup>23</sup>, Monica Slavin<sup>24</sup>, Benjamin Teh<sup>24</sup>, Cesar
- 13 A Arias<sup>2</sup>, Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE)
- 14 Team<sup>25</sup>, Dimitrios P. Kontoyiannis<sup>1</sup>, Alexandre E. Malek<sup>1</sup>, Anne-Marie Chaftari\*<sup>†1</sup>
- \*Contributed equally
- †Corresponding Author
- 17 Department of Infectious Diseases, Infection Control and Employee Health, The University of
- 18 Texas MD Anderson Cancer Center, Houston, Texas, USA
- <sup>2</sup> Division of Infectious Diseases, McGovern Medical School, The University of Texas Health
- 20 Science Center at Houston, Houston, Texas, USA
- <sup>3</sup> Médica Hematologista Hospital Israelita Albert Einstein, São Paulo, Brasil

- <sup>4</sup> Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson
- 23 Cancer Center, Houston, Texas, USA
- <sup>5</sup>MD Anderson Cancer Network, UT MD Anderson Cancer Center, Houston, Texas, USA
- <sup>6</sup> Department of Hematology Oncology, Community Health Network, Indiana, USA
- <sup>7</sup> Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France
- <sup>8</sup> Cooper Medical School of Rowan University, Cooper University Health Care, Camden, New
- 28 Jersey, USA
- <sup>9</sup> Unidad de Enfermedades Infecciosas, Servicio de Medicina Interna, Hospital Universitario
- 30 Puerta de Hierro, Madrid, Spain
- 31 Department of Hematology Oncology, Baptist Health, Jacksonville, Florida, USA
- 32 <sup>11</sup>Department of Hematology/Oncology, Ohio Health Marion, Ohio, USA
- <sup>12</sup> Department of Infectious Diseases, St. Luke's International Hospital, Tokyo, Japan
- 34 <sup>13</sup>Banner MD Anderson Cancer Center North Colorado, Greely, Colorado, USA
- 35 Division of Cancer Medicine, Banner MD Anderson Cancer Center, Gilbert, Arizona, USA
- 36 <sup>15</sup> Department of Medical Oncology, Tan Tock Seng Hospital, Singapore
- 37 <sup>16</sup> Department of Infectious Diseases, Rafik Hariri University Hospital, Beirut, Lebanon
- 38 <sup>17</sup> Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center,
- 39 Houston, Texas
- 40 <sup>18</sup> Department of Gastroenterology, The University of Texas MD Anderson Cancer Center,
- 41 Houston, Texas

- 42 <sup>19</sup> Department of Hospital Medicine, The University of Texas MD Anderson Cancer Center,
- 43 Houston, Texas
- <sup>20</sup> Department of Breast Surgical Oncology, The University of Texas MD Anderson Cancer
- 45 Center, Houston, Texas
- 46 <sup>21</sup> Oncology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
- 47 <sup>22</sup> Hematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid,
- 48 Spain
- 49 <sup>23</sup> Division of Infectious Diseases, Department of Internal Medicine, Vaccine Bio Research
- 50 Institute, The Catholic University of Korea, Seoul, Korea
- 51 <sup>24</sup> Department of Infectious Diseases and National Centre for Infections in Cancer, Peter
- 52 MacCallum Cancer Centre, Melbourne, Victoria, Australia
- 53 <sup>25</sup>Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team at The
- 54 University of Texas MD Anderson Cancer Center, Houston, TX
- 55 Corresponding authors: Anne-Marie Chaftari & Ray Hachem, Department of Infectious
- 56 Diseases, Infection Control and Employee Health, The University of Texas MD Anderson
- 57 Cancer Center, 1515 Holcombe Blvd., Unit 1460, Houston, TX 77030, USA. Tel: 713-792-3491,
- Email: achaftari@mdanderson.org; rhachem@mdanderson.org
- **Keywords:** COVID-19, coronavirus, cancer patients, non-cancer patients.
- 60 Word count: 3058

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

all-cause mortality.

**ABSTRACT Background:** In this international multicenter study we aimed to determine the independent risk factors associated with increased 30-day mortality and the impact of novel treatment modalities in a large group of cancer and non-cancer patients with COVID-19 from multiple countries. **Methods:** We retrospectively collected de-identified data on a cohort of cancer and non-cancer patients diagnosed with COVID-19 between January and November 2020, from 16 international centers. **Results:** We analyzed 3966 COVID-19 confirmed patients, 1115 cancer and 2851 non-cancer patients. Cancer patients were more likely to be pancytopenic, and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding two weeks ( $p \le 0.01$ ). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin and procalcitonin), but were less likely to present with clinical symptoms (p≤0.01). By multivariable logistic regression analysis, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035). Older age ( $\geq$ 65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to 6.20; p < 0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30day mortality (OR 0.58; CI 0.39-0.88; p=0.009). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30-day mortality rate than those who did not (5.9% vs 17.6%; p=0.03). **Conclusions:** Cancer is an independent risk factor for increased 30-day all-cause mortality from COVID-19. Remdesivir, particularly in patients receiving low-flow oxygen, can reduce 30-day

# **Condensed Abstract**

- In this large multicenter worldwide study of 4015 patients with COVID-19 that included 1115
- patients with cancer, we found that cancer is an independent risk factor for increased 30-day all-
- 87 cause mortality. Remdesivir is a promising treatment modality to reduce 30-day all-cause
- 88 mortality.

**INTRODUCTION** The COVID-19 pandemic has challenged the health care system worldwide and has spread to more than 200 countries, causing hundreds of millions confirmed cases and several million deaths.1 Data from multiple studies have shown consistently that older age and comorbidities such as cardiovascular disease, diabetes mellitus (DM), hypertension, and chronic obstructive pulmonary disease (COPD)have been associated with severe illness and increased mortality.<sup>2</sup> Several studies on COVID-19 mortality suggested that cancer patients had poor outcomes.<sup>3</sup>-Many of these studies included only cancer patients and did not have a comparator group of noncancer patients.<sup>3-7</sup> Other studies compared COVID-19 mortality between cancer and non-cancer patients and found that cancer patients had worse outcomes. 9-13 However, all of these comparative studies included a relatively small number of cancer patients and were restricted to a particular country, which limits their generalizability to cancer patients worldwide. Given that many of the therapeutic studies on COVID-19 were conducted in non-cancer patients and given the poor outcomes of COVID-19 reported in cancer patients, 9-18 we aimed to conduct a large multicenter study to compare the impact of these various treatments on the outcome in cancer versus non-cancer patients. Therefore, given the global spread of the COVID-19 pandemic and the worldwide prevalence of cancer, we undertook this international initiative that included 16 centers from five continents to study and compare the clinical course, risk factors and treatment modalities impact on outcomes in cancer versus non-cancer patients with COVID-19 on a worldwide basis.

# Methods

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

Study design and participants This was a retrospective international multicenter study that included all patients diagnosed with COVID-19 by real-time polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the site or an outside facility between January 4, 2020, and November 15, 2020. The study involved 16 centers from 9 countries, eight centers in the United States and one each in Australia, Brazil, France, Japan, Lebanon, Singapore, South Korea, and Spain. Patients were divided into two groups: non-cancer and cancer patients diagnosed or treated within a year before the diagnosis of COVID-19. Multicenter collaboration and data collection The University of Texas MD Anderson Cancer Center was the coordinating center that designed the study, built the electronic case report form and collected de-identified patient information from all participating centers using the secure Research Electronic Data Capture platform. We reviewed each patient's electronic hospital record and collected all needed data. This study was approved by the institutional review board at MD Anderson Cancer Center and the institutional review boards of the collaborating centers. A patient waiver of informed consent was obtained. The follow-up period was defined as 30 days after a diagnosis of COVID-19. Neutropenia was defined as an absolute neutrophil count <500 cells/mL. Lymphopenia was defined as an absolute lymphocyte count <500 cells/mL. **Treatment modalities** For each patient, data were collected on COVID-19 treatments, including antimicrobial therapy and potential antiviral therapy. We evaluated patient's oxygen requirement: low-flow was defined

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

as oxygen supplementation of  $\leq 6$  liters/minute through a nasal cannula or facemask, and highflow included all other modalities of oxygen supplementation, including mechanical ventilation. **Outcomes measures** The primary outcome of interest was 30-day mortality. The secondary outcomes included mechanical ventilation, progression to lower respiratory tract infection, co-infection, and hospital readmissions within 30 days after COVID-19 diagnosis. **Statistical analysis** Patient characteristics and outcomes were compared between COVID-19 patients with and without cancer. Categorical variables were compared using chi-square or Fisher's exact test, and continuous variables compared using Wilcoxon rank sum test. Kaplan-Meier curves were estimated and compared using a log-rank test. A multivariable logistic regression model was used to identify the independent predictors of 30-day mortality in all patients and in cancer patients and non-cancer patients among the following factors: patients' demographic and clinical characteristics, medical history, laboratory findings at diagnosis, and treatment. In cancer patients, the mortality rates of patients with different types of cancer were estimated and compared. Lastly, the impacts on mortality of certain therapeutic agents and their timing of administration were evaluated using chi-square or Fisher's exact test. All statistical tests were two-sided with a significance level of 0.05. The analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC). **RESULTS** A total of 4015 patients diagnosed with COVID-19 by PCR were included in the study. After excluding 18 patients who had missing demographics and 31 patients younger than 18 years, we evaluated 3966 COVID-19 patients: 2851 non-cancer and 1115 cancer patients.

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

Demographics and clinical characteristics of patients with and without cancer Patient characteristics are presented in Table 1. Compared to non-cancer patients, cancer patients were older (median age, 61 vs 50 years; p<0.0001); more likely to have a smoking history (38%) vs 17%; p<0.0001), pulmonary disorder (27% vs 21%; p<0.001), hypertension (49% vs 36%, p<0.0001), DM (27% vs 23%, p=0.01), or corticosteroid use in the two weeks preceding COVID-19 diagnosis (17% vs 4%, p<0.0001); and less likely to present with clinical symptoms, including cough (46% vs 65%; p<0.0001), fever (45% vs 66%; p<0.0001), and shortness of breath (35% vs 48%; p<0.0001). Compared to non-cancer patients, cancer patients were more likely to present with neutropenia (7% vs 0.1%; p<0.0001), lymphocytopenia (49% vs 32%; p<0.0001), thrombocytopenia (39% vs 13%; p<0.0001), and anemia (47% vs 29%; p<0.0001) and had higher median levels of inflammatory biomarkers, including D-dimer, ferritin, and procalcitonin. On imaging studies (computed tomography), cancer patients were less likely than non-cancer patients to present with ground-glass opacities (68% vs 78%; p<0.0001) or peripheral distribution of the infiltrates (17% vs 41%; p<0.0001). Treatment and outcomes of patients with and without cancer The rate of COVID-related hospital admission was higher in the non-cancer patients (64% vs 57%; p<0.001). Co-infections occurred more frequently in cancer patients (11% vs 8%; p=0.006). Among hospitalized patients, cancer patients were more likely than non-cancer patients to be discharged on supplemental oxygen (17% vs %; p=0.007). Likewise, the rate of hospital readmission within 30 days was higher in cancer patients (13% vs 7%; p<0.0001). Furthermore, the mortality rate within 30 days was significantly higher in cancer patients (11%) vs 8%; p=0.003) (Table 1 and Figure 1).

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

Risk factors for death within 30 days after COVID-19 diagnosis Of the total 3966 patients 348 died within 30 days (8.8%) and of them 189 had data available for their cause of death, which showed 93% (176/189) of the deaths were COVID-19 related. In the multivariable logistic regression analysis including all patients, cancer was an independent risk factor for 30-day mortality (OR 1.46; 95% CI 1.03 to 2.07; p=0.035) even though cancer patients were less frequently hospitalized and less frequently received corticosteroids and remdesivir (Figure 2). Older age (≥65 years) was the strongest predictor of 30-day mortality in all patients (OR 4.55; 95% CI 3.34 to 6.20; p<0.0001) and in both cancer and non-cancer patients (Figures 2 & 3). Other independent risk factors for 30-day mortality in all patients included hypoxia at diagnosis (OR 3.21; 95% CI 2.18 to 4.71; p<0.0001), need for mechanical ventilation (OR 2.37; 95% CI 1.34 to 4.18; p=0.003), and presence of co-infection (OR 1.86; 95% CI 1.28 to 2.70; p=0.001) (Figure 2). In cancer patients, lower respiratory tract infection manifested by the presence of pulmonary infiltrates either at diagnosis or during the course of infection was a strong independent predictor of 30-day mortality (OR 3.70; 95% CI 1.94 to 7.08; p<0.0001) (Figure 3). Among cancer patients, the 30-day mortality rate was significantly higher in patients with lung cancer than in patients with non-lung cancer solid tumors, including those with lung metastases (p<0.001; Table 2). Patients with hematologic malignancies had a significantly higher 30-day mortality than patients with non-lung cancer solid tumors (p<0.001) but tended to have a lower mortality rate than patients with lung cancer (p=0.07; Table 2). We did not find a significant difference in mortality between hematological malignancies and solid tumors by multivariate analysis (p=0.30).

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

By multivariate analysis, remdesivir was the only therapeutic agent independently associated with decreased 30-day all-cause mortality in all patients (OR 0.58; 95% CI 0.39 to 0.88; p=0.009) (Figure 2), in cancer patients (OR 0.44; 95% CI 0.20 to 0.96; p=0.04) and non-cancer patients (OR 0.61; 95% CI 0.38 to 0.98; p=0.04) (Figure 3). Among patients on low-flow oxygen at admission, the mortality rate was lower among those who received remdesivir than among those who did not (5.9% [3 of 51] vs 17.6% [68 of 387]; p=0.03). However, among patients on high-flow oxygen at admission, there was no difference in the mortality rate between patients who received remdesivir and those who did not (29.7% [11 of 37] and 34.4% [53 of 154], respectively; p=0.59). Since 85% of patients treated with remdesivir also received corticosteroids, we evaluated the impact of their combination therapy on 30-day mortality. Among patients on low-flow oxygen at admission, the mortality rates among those who received remdesivir alone or in combination with corticosteroids (0% [0 of 8] and 7.0% [3 of 43], respectively) tended to be lower than the mortality rate of those who received corticosteroids alone (18.3% [21 of 115]; p=0.10). However, mortality rates were similar for remdesivir alone and combination therapy among various patients' groups (Table 3). We then evaluated the impact of timing administration of different agents on 30-day mortality. We found that patients who died within 30 days were less likely to be transfused with convalescent plasma within 1 day of COVID-19 diagnosis (which likely occurs 2-3 days after symptom onset) than patients who survived (1% vs 7%, p=0.04; Supplemental Table 1). Giving convalescent plasma to patients later than 3 days after diagnosis did not make any difference in mortality (Supplemental Table 1). In contrast to what was observed for convalescent plasma, the later corticosteroids were administered, the greater the benefit. There was a trend toward a

228

229

230

231

232

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

greater reduction in 30-day mortality in patients who received corticosteroids later (>5 days after diagnosis), whereas no difference was observed in patients who received corticosteroids earlier. **DISCUSSION** Unlike the previously published studies that compared patients with COVID-19 with and without cancer, our study included a large number of cancer patients from five different continents. Our findings demonstrate that cancer is an independent risk factor for increased 30day all-cause mortality, which is consistent with a recent large study in the US that also showed that patients recently receiving cancer treatment had a worse outcome. <sup>19</sup> Furthermore, this higher mortality rate in cancer patients seems to be driven by patients with lung cancer and patients with hematologic malignancies, a finding that is consistent with prior literature. 8,9 The mortality rate in the patients with solid tumors other than lung cancer was not different from the mortality rate in the non-cancer patients. Most of the other independent risk factors that we identified for 30day mortality after a diagnosis of COVID-19 have also been commonly reported as risk factors for mortality in previous studies of COVID-19 in cancer and non-cancer patients.<sup>2-13</sup> In addition to a higher 30-day mortality rate, the cancer patients in our study had a more complicated course after discharge from the hospital; specifically, they more frequently required supplemental oxygen and readmission within 30 days after COVID-19 diagnosis. The presentation pattern of cancer patients with COVID-19 was different to that of non-cancer patients. Cancer patients seemed to be less symptomatic. This could be related to the fact that cancer patients tended to be older, with fewer inflammatory cells (neutrophils and lymphocytes), and more often on corticosteroids. Levels of inflammatory biomarkers were also higher in patients with cancer, particularly D-dimer, ferritin, and pro-calcitonin.

250

251

252

253

254

255

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

On multivariate analysis, the only therapeutic agent that independently decreased 30-day allcause mortality in both cancer patients and non-cancer patients was remdesivir. Upon further analysis, remdesivir was found to further decrease mortality in patients with pneumonia and mild hypoxia who were receiving low-flow oxygen (≤6 liters per minute) and not in patients with severe advanced pneumonia who were receiving high-flow oxygen and/or ventilatory support. In a large multicenter prospective randomized placebo-controlled trial (ACTT-1) evaluating remdesivir in 1062 patients with COVID-19 pneumonia, this agent was found to be associated with a quicker recovery than placebo. <sup>14</sup> In a further subgroup analysis, remdesivir was found to significantly reduce the time to recovery and 28-day mortality in patients who were on low-flow oxygen at baseline but not in patients who were on mechanical ventilation or extracorporeal membrane oxygenation at baseline. <sup>14</sup> Hence, the results of this large prospective randomized study, particular the results of the subgroup analysis, are consistent with our findings. In a meta-analysis that examined four large prospective randomized trials, remdesivir was shown to be associated with reduced 14-day mortality and reduced need for mechanical ventilation, <sup>20</sup> which also supports our analysis. In contrast, the World Health Organization (WHO)-- sponsored multinational Solidarity Trial of COVID-19 hospitalized patients who were randomly assigned to either remdesivir (2750 patients) or standard of care (2708 patients) showed no difference in overall 28-day mortality.<sup>21</sup> However, in two large meta-analyses that each examined more than 13,000 COVID-19 patients from randomized and non-randomized studies, including the WHO randomized trial, remdesivir was associated with a significant improvement in the 28-day recovery rate. <sup>22,23</sup> Furthermore, in a large study evaluating treatments and outcomes among cancer patients with COVID-19, remdesivir alone was significantly associated with a lower 30-day all-cause mortality rate than

273

274

275

276

277

278

279

280

281

282

283

284

285

286

287

288

289

290

291

292

293

294

other treatments (including high-dose corticosteroids and tocilizumab). In addition, in a large multicenter matched controlled study involving mostly noncancer patients, Mozaffari E et al. demonstrated that remdesivir, was significantly effective in reducing mortality in patients on low-flow oxygen but not patients with advanced disease on high-flow oxygen and ventilator support.<sup>24</sup> More recently a prospective randomized, double blind, placebo-controlled study (involving mainly non-cancer patients) showed that early initiation of remdesivir prevents progression to severe COVID-19.<sup>25</sup> Therefore, the cumulative data in the literature do support our finding that remdesivir in all patients (cancer and non-cancer patients) improves outcome and may reduce mortality in patients with COVID-19, particularly in patients with moderate pneumonia who are receiving low-flow oxygen. Such patients are in stage II of the three-stage COVID-19 classification previously proposed by Siddigi et al.<sup>26</sup> In that classification, stage I is mild illness and high-level viral replication that all patients go through and most (>80%) recover from. It is during this stage, where the new antiviral agents (Ritonavir – Boosted Nirmatrelvir and Molnupiravir) were found to be highly effective in reducing the risks of hospitalization and death among high risk patients with COVID-19. 27,28 Stage II is moderate pneumonia, which includes early hypoxia necessitating low-flow oxygen. Patients with stage II COVID-19 benefit from early remdesivir since viral replication continues in association with host inflammatory response in accordance with our data, the literature, and the Siddiqi et al therapeutic model. Stage III is the hyperinflammatory phase with severe pneumonia and extrapulmonary system manifestations. Patients with disease that has progressed into this hyperinflammatory late stage with severe pneumonia and hypoxia requiring high-flow oxygen and ventilatory support do not seem to benefit from remdesivir or other antiviral therapy but could benefit from anti-inflammatory agents such as corticosteroids.

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

The use of corticosteroids (dexamethasone 6 mg/day) was shown in a large randomized openlabel study conducted in the United Kingdom to be associated with reduced 28-day mortality, particularly in patients requiring oxygen supplementation and invasive ventilation who receive corticosteroids after 7 days from the onset of symptoms. 18 Subsequently, two meta-analyses of several prospective randomized trials demonstrated that corticosteroid use was significantly associated with a decrease in COVID-19 mortality. <sup>29,30</sup> In our study, we found that if corticosteroids were started more than 5 days after the PCR diagnosis of COVID-19, there was a trend towards a reduction in 30-day COVID-19 mortality compared to starting corticosteroids earlier. Five days after diagnosis by PCR testing would possibly be equivalent to 7 days after the onset of symptoms since the average time from symptom onset to PCR diagnosis has been estimated to be 2 to 3 days. <sup>31</sup> Furtheremore, by multivariate analysis and upon further subanalysis (Table 3), remdesivir was found to improve outcome independently of the effect of steroids. With regard to convalescent plasma treatment, multivariate analyses from our study did not show any overall benefit. This finding is consistent with a meta-analysis of randomized controlled trials comparing convalescent plasma to standard of care. <sup>17</sup> However, when convalescent plasma was given very early after diagnosis (within 1 day of COVID-19 diagnosis, which is estimated to be around 3 days after symptom onset), this intervention was associated with a significant reduction of COVID-19-related 30-day mortality compared to the late intervention. Several studies have shown that early transfusion (within 3 days of hospital admission) of high-titer plasma may be associated with an improved clinical outcome of COVID-19. 15,16,32,33 The lack of benefit noted in several studies of convalescent plasma could be related to delayed administration of convalescent plasma, in the advanced hyperinflammatory stages of COVID-19,

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

rather than administration in the early stage when viral replication is at its highest and neutralizing antibodies in convalescent plasma could be most effective, as previously noted by Siddiqi et al., early during the infection. 15-18,20-23,26 Our study has several limitations. First, the retrospective design precluded complete assessment of disease progression in the outpatients, which limited their input into the general study. Second, some non-cancer centers contributed data only on their hospitalized patients who were likely sicker. This may have biased the data towards a higher rate of hospitalization among noncancer patients and made the data more heterogeneous. In addition, the predominance of symptomatic patients (87%) might also limit our evaluation of the impact of cancer in the whole picture of the disease. Third, there were differences in responses to COVID-19 from one geographic area to another. Patients diagnosed with COVID-19, may have been treated differently according to specific national guidelines. For example, the 30-day all-cause mortality rate was lower at centers in the United States than at centers in Latin America or Asia. This could have been related to the accessibility or early initiation of some interventions in the United States, such as remdesivir or convalescent plasma, which made data more heterogeneous. We did not evaluate the accessibility and timing of interventions in the treating facilities. Last, this study was conducted prior to the introduction of COVID vaccines and included patients who were not vaccinated and who were infected by early variants which limits the generalizability of our results to contemporary COVID-19 patients. In conclusion, this is the largest multicenter worldwide study comparing cancer patients to noncancer patients with COVID-19. In this study, although the limited effect size, underlying malignancy was found to be an independent risk factor for a higher 30-day all-cause COVID-19 mortality, with lung cancer and hematologic malignancies associated with the highest risks for

poor outcome. Finally, remdesivir stood out as the only therapeutic agent independently associated with decreased 30-day mortality, particularly in patients on low-flow oxygen.

Corticosteroids tended to be most useful if given more than 5 days after COVID-19 diagnosis.

The role of these therapeutics and their timing of administration should be verified in larger studies, especially in cancer patients, who tend to have a higher degree of immunosuppression, which may lead to prolongation of the viral phase.

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

**Contributors** IR, RH, AMC were responsible for study conception, protocol design, writing of the first draft and coordinating the manuscript. RH, NM, TD, HD, BS, AB, RS, AFC, EG, AB, NM, NH, SS, TD, YEVK, SF, PAH, JB, FK, BG, TJ, EYG, HT, NRA, MY, CCRG, MP. NA. RDR, SMA, RED, TM, KI, RH, RAN, AGG, CTP, DGL, MS, FT, AEM, and AMC were responsible for data collection at their respective sites. YJ designed the statistical analysis plan, analyzed the data, developed the figures and the tables. IR, RH, HD, YJ, VS, AEM, and AMC had access to all the data and were responsible for overall project and data management. All authors had full access to the study data and had final responsibility for the decision to submit for publication. All authors were responsible for critical review of drafts and approval of the final manuscript." **Data sharing** The study protocol, statistical analysis plan, lists of deidentified individual data, generated tables and figures will be made available upon request by qualified scientific and medical researchers for legitimate research purposes. Requests should be sent to achaftari@mdanderson.org and vijiang@mdanderson.org. Data will be available on request for 6 months from the date of publication. Investigators are invited to submit study proposal requests detailing research questions and hypotheses in order to receive access to these data. **Declaration of interests** We declare no competing interests. **Funding** National Cancer Institute, National Institutes of Health

Table 1. Comparing COVID-19 patients with and without cancer

Characteristic	Without Cancer	With Cancer	<i>p</i> -value
	(n=2851)	(n=1115)	·
	N (%)	N (%)	
Demographic and baseline clinical characteristics			
Age (years), median (range)	50 (18-100)	61 (18-100)	< .0001
Sex, male	1335 (47)	506 (45)	0.41
Race/ethnicity			< .0001
White	720/2674 (27)	534/916 (58)	
Black	517/2674 (19)	155/916 (17)	
Hispanic	547/2674 (20)	178/916 (19)	
Asian	275/2674 (10)	33/916 (4)	
Middle Eastern	63/2674 (2)	3/916 (0.3)	
Other	552/2674 (21)	13/916 (1)	
Prior pulmonary disorders	431/2064 (21)	275/1017 (27)	< .001
COPD/bronchiolitis obliterans	175/2054 (9)	75 (7)	0.07
Asthma	178 (6)	106 (10)	< .001
Obstructive sleep apnea	98/2054 (5)	89/948 (9)	< .0001
History of heart failure	240/2036 ()	85/1098 (8)	< .001
History of hypertension	1020/2837 (36)	546/1110 (49)	< .0001
History of diabetes mellitus	659/2837 (23)	299/1104 (27)	0.01
Current or previous smoker	348/2055 (17)	409/1066 (38)	< .0001
Corticosteroid treatment within 2 weeks prior to COVID-19	( (-)		
diagnosis	40/1041 (4)	189/1097 (17)	< .0001
Presenting symptoms	981/1061 (92)	813/1102 (74)	< .0001
Cough	685/1061 (65)	505/1102 (46)	< .0001
Fever	698/1061 (66)	498/1102 (45)	< .0001
Shortness of breath	508/1061 (48)	387/1102 (35)	< .0001
Chest pain	100/1061 (9)	66/1102 (6)	0.003
Headache	133/1061 (13)	80/1102 (7)	< .0001
Gastrointestinal symptoms	148/1061 (14)	104/1102 (9)	0.001
Loss of smell	84/1061 (8)	58/1102 (5)	0.013
Loss of taste	78/1061 (7)	55/1102 (5)	0.022
ICU admission	225/1846 ()	141/1100 (13)	0.62
Abnormal laboratory values			
ANC < 0.5 K/μL	2/1434 (0.1)	30/419 (7)	< .0001
ALC < 0.5 K/μL	487/1537 (32)	225/463 (49)	< .0001
Platelet count < 100 K/μL	187/1446 (13)	151/387 (39)	< .0001
Hemoglobin < 10 g/dL	437/1533 (29)	283/601 (47)	< .0001
D-dimer, median (range), mcg/ml	1.51 (0.04-735.0)	1.95 (0.25-93.24)	0.013
Ferritin, median (range), ng/ml	823 (1.10-89672)	1015 (1.5-100001)	< .0001
Procalcitonin, median (range), ng/ml	0.21(0.009-163.5)	0.25(0-101.8)	0.008
IL-6, median (range), pg/ml Imaging findings	61 (0-5001)	44 (0-7525)	0.13

New infiltrates	151/622 (24)	138/424 (33)	0.003
Ground-glass opacities	487/622 (78)	287/425 (68)	< .0001
Peripheral distribution of infiltrates	253/622 (41)	60/347 (17)	< .0001
Outcomes			
Co-infection after COVID-19 diagnosis	158/1994 (8)	116/1066 (11)	0.006
Multi-organ failure	130/1052 ()	135/1096 ()	0.98
Thrombotic complication	56/1048 (5)	48/1072 (5)	0.36
Discharged on supplemental oxygen among hospitalized	90/776 ()	75/438 (17)	0.007
patients			
Hospital re-admission within 30 days of COVID-19 diagnosis			< .0001
No	667/806 (83)	318/481 (66)	
Yes	60/806 (7)	63/481 (13)	
Stayed in hospital (throughout 30 days)	79/806 (10)	100/481 (21)	
Death within 30 days of COVID-19 diagnosis	226 (8)	122/1115 (11)	0.003

Abbreviations: COPD=Chronic obstructive pulmonary disease; ANC=Absolute neutrophil count; ALC=Absolute lymphocyte count; IL-1=interleukin 1; IL-6=Interleukin 6; COVID-19=Coronavirus disease 2019; NA=Not applicable.

# Table 2. 30-Day mortality among different groups of cancer patients with COVID-19

## a) Cancer type

376

377

Patient group	No. of patients	No. (%) who died within 30
		days*
Hematologic malignancy	283	37 (13)
Transplant within 1 year of COVID-19 diagnosis	15	2 (13)
Lymphoma or myeloma	164	19 ()
Lymphocytic leukemia (ALL/CLL)	44	6 (14)
Myelocytic leukemia	62	8 (13)
Solid tumor†	632	47 (7)
Lung cancer	64	14 (22)
Metastatic non-lung cancer solid tumor	261	17 (7)
Non-metastatic non-lung cancer solid tumor	307	16 (5)

#### Notes:

378

379

380

381

382

383

# \*30-day mortality comparisons:

- 1) Lung cancer vs metastatic non-lung cancer solid tumor: p< 0.001
- 2) Lung cancer vs non-metastatic non-lung cancer solid tumor: p< 0.0001
- 4) Hematologic malignancy vs lung cancer: p=0.07
- 5) Hematologic malignancy vs non-lung cancer solid tumor: p< 0.001
- 6) None of the above significant differences detected remained significant in multivariable analysis of 30-day mortality in cancer patients (Figure 3A)

## b) Cancer status and treatment

Variable	30-Day	<i>p</i> -value		
	No	Yes	_	
	(n=993)	(n=122)		
	N (%)	N (%)		
Cancer status			0.10	
Being treated initially	342/906 (38)	31/97 (32)		
Remission	338/906 (37)	32/97 (33)		
Refractory/relapse	226/906 (25)	34/97 (35)		
Chemotherapy within one year prior to COVID-19 diagnosis	428/983 (44)	57/120 (48)	0.41	
Transplant within one year prior to COVID-19 diagnosis Immunotherapy within 6 months prior to COVID-19	11/968 (1)	2/122 (2)	0.65	
diagnosis	46/757 (6)	5/63 (8)	0.58	
Radiotherapy within 6 months prior to COVID-19 diagnosis	96/982 (10)	13/118 (11)	0.67	

 $<sup>\</sup>ensuremath{^{\dagger}}$  Patients with missing metastasis data were excluded from the analysis.

Table 3. Comparing Mortality in Patients Treated with Remdesivir Alone or with Steroids for COVID-19.

Patients groups	Outcome	Remdesivir and steroids	Remdesivir alone	<i>p</i> -value
All patients	30-Day death	62/370 (16.8%)	/65 (18.5%)	0.74
Patients with Hypoxia	30-Day death	58/336 (17.3%)	10/53 (18.9%)	0.77
With low-flow oxygen	30-Day death	3/43 (7%)	0/8 (0%)	>.99
With high-flow oxygen	30-Day death	5/18 (27.8%)	6/19 (31.6%)	0.8
On ventilation at diagnosis	30-Day death	26/146 (17.8%)	7/30 (23.3%)	0.48

Supplemental Table 1. Timing of administration of convalescent plasma and corticosteroids as COVID-19 treatment and 30-day mortality

Treatment and timing of initiation in			
relation to COVID-19 diagnosis	Alive	Dead	<i>p</i> -value
	N/n (%)	N/n (%)	
Convalescent plasma			
≤ 1 day	14/196 (7)	1/88 (1)	0.04
> 1 days	182/196 (93)	87/88 (99)	
≤ 2 days	49/196 (25)	17/88 (19)	0.3
> 2 days	147/196 (75)	71/88 (81)	
≤ 3 days	80/196 (41)	37/88 (42)	0.9
> 3 days	116/196 (59)	51/88 (58)	
Corticosteroids			
≤ 3 days	594/789 (75)	131/165 (79)	0.3
> 3 days	195/789 (25)	34/165 (21)	
≤ 4 days	633/789 (80)	139/165 (84)	0.2
> 4 days	156/789 (20)	26/165 (16)	
≤ 5 days	665/789 (84)	147/165 (89)	0.1
> 5 days	4/789 (16)	18/165 (11)	
≤ 6 days	700/789 (89)	153/165 (93)	0.1
> 6 days	89/789 (11)	/165 (7)	

Note: Diagnosis of COVID-19 by PCR occurs around 2-3 days after onset of symptoms.

Figure 1. Kaplan-Meier mortality curves of COVID-19 patients with and without cancer (N=3956).

Figure 2. Independent predictors of 30-day mortality of COVID-19 patients by multivariable logistic regression analysis (N=2349).

Figure 3. Independent predictors of 30-day mortality of COVID-19 patients with cancer (A) and without cancer (B) by multivariable logistic regression analysis.

Acknowledgments

- We thank all the investigators, MD Anderson Cancer Network, and the Data-Driven
- Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team at The University of
- Texas MD Anderson Cancer Center for assistance in study development and data extraction.
- We thank Ms. Meena Medepalli and Mr. Joel Cox from the MD Anderson Cancer Network -
- External Research at The University of Texas MD Anderson Cancer Center for their support in
- 421 coordinating the cancer network sites for protocol participation.
- We thank Mr. Joseph P. Thomas at The University of Texas MD Anderson Cancer Center for his
- assistance with data capture in REDCap, Kris Weaver for data quality review, Sheri Rivera for
- REDCap build, Regulatory team for the fast activation, Toby and her team for assistance in
- resolving IT issues with site EMR.

413 414

415

418

422

427

434

437


441

- We thank Anastasia Turin and Drew Goldstein from Syntropy Technologies LLC, Burlington,
- MA for interfacing with the Syntropy platform: Palantir Foundry. "Foundry" is Syntropy's fully-
- managed, cloud-based software-as-a-service for governing, structuring, and harmonizing real-
- world data to empower health systems and their collaborators to derive insights from that data.
- Editorial assistance was provided by Stephanie P Deming, Research Medical Library at MD
- Anderson. This assistance was funded by The University of Texas MD Anderson Cancer Center.
- We thank Ms. Salli Saxton and Ms Christine Cobb at The University of Texas MD Anderson
- Cancer Center for helping with the submission of the manuscript.
- Funding/Support: This research is supported by the National Institutes of Health/National
- Cancer Institute under award number P30CA016672, which supports the MD Anderson Cancer
- 440 Center Clinical Trials Office.
- Role of the Funder/Support: The funders had no role the design and conduct of the study;
- collection, management, analysis, and interpretation of the data; preparation, review, or approval
- of the manuscript; and decision to submit the manuscript for publication.


## References

- 451 1. COVID-19 Map Johns Hopkins Coronavirus Resource Center
- 452 https://coronavirus.jhu.edu/map.html (accessed April 29, 2021.
- 2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with
- 454 COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; **395**(10229): 1054-62.
- 455 3. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer 456 (CCC19): a cohort study. *Lancet* 2020; **395**(10241): 1907-18.
- 457 4. Rivera DR, Peters S, Panagiotou OA, et al. Utilization of COVID-19 Treatments and Clinical
- Outcomes among Patients with Cancer: A COVID-19 and Cancer Consortium (CCC19) Cohort Study.
- 459 *Cancer Discov* 2020; **10**(10): 1514-27.
- He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. *Leukemia* 2020;
- 461 **34**(6): 1637-45.
- 462 6. Albiges L, Foulon S, Bayle A, et al. Determinants of the outcomes of patients with cancer
- infected with SARS-CoV-2: results from the Gustave Roussy cohort. *Nat Cancer* 2020; **1**(10): 965.
- 7. Robilotti EV, Babady NE, Mead PA, et al. Determinants of COVID-19 disease severity in patients with cancer. *Nat Med* 2020; **26**(8): 18-23.
- 466 8. Lee LY, Cazier JB, Angelis V, et al. COVID-19 mortality in patients with cancer on chemotherapy
- or other anticancer treatments: a prospective cohort study. *Lancet* 2020; **395**(10241): 1919-26.
- 9. Mehta V, Goel S, Kabarriti R, et al. Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System. *Cancer Discov* 2020; **10**(7): 935-41.
- 470 10. Tian J, Yuan X, Xiao J, et al. Clinical characteristics and risk factors associated with COVID-19
- disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study.
- 472 Lancet Oncol 2020; **21**(7): 893-903.
- 473 11. Lunski MJ, Burton J, Tawagi K, et al. Multivariate mortality analyses in COVID-19: Comparing
- patients with cancer and patients without cancer in Louisiana. *Cancer* 2021; **7**(2): 266-74.
- Sun L, Sanjna S, Le A, et al. Rates of COVID-19-related Outcomes in Cancer compared to non-
- 476 Cancer Patients. *medRxiv* 2020.
- 477 13. Ruthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer patients: clinical
- characteristics and outcome-an analysis of the LEOSS registry. Ann Hematol 2021; **100**(2): 383-93.
- 479 14. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 Final Report.
- 480 N Engl J Med 2020; **383**(19): 1813-26.
- 481 15. Salazar E, Christensen PA, Graviss EA, et al. Significantly Decreased Mortality in a Large Cohort of
- 482 Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing
- 483 High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. Am J
- 484 *Pathol* 2021; **191**(1): 90-107.
- 485 16. Libster R, Perez Marc G, Wappner D, et al. Early High-Titer Plasma Therapy to Prevent Severe
- 486 Covid-19 in Older Adults. *N Engl J Med* 2021; **384**(7): 610-8.
- 487 17. Janiaud P, Axfors C, Schmitt AM, et al. Association of Convalescent Plasma Treatment With
- 488 Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. *JAMA* 2021.
- 489 18. Recovery CG, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N
- 490 *Engl J Med* 2021; **384**(8): 693-704.
- 491 19. Chavez-MacGregor M, Lei X, Zhao H, Scheet P, Giordano SH. Evaluation of COVID-19 Mortality
- 492 and Adverse Outcomes in US Patients With or Without Cancer. JAMA Oncol 2021.
- 493 20. Shrestha DB, Budhathoki P, Syed NI, Rawal E, Raut S, Khadka S. Remdesivir: A potential game-
- changer or just a myth? A systematic review and meta-analysis. Life Sci 2021; **264**: 118663.
- 495 21. W. H. O. STC, Pan H, Peto R, et al. Repurposed Antiviral Drugs for Covid-19 Interim WHO
- 496 Solidarity Trial Results. *N Engl J Med* 2021; **384**(6): 497-511.

- 497 22. Rezagholizadeh A, Khiali S, Sarbakhsh P, Entezari-Maleki T. Remdesivir for treatment of COVID-
- 498 19; an updated systematic review and meta-analysis. Eur J Pharmacol 2021; 897: 173926.
- 499 23. Lai CC, Chen CH, Wang CY, Chen KH, Wang YH, Hsueh PR. Clinical efficacy and safety of
- remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized
- 501 controlled trials. J Antimicrob Chemother 2021.
- 502 24. Mozaffari E, Chandak A, Zhang Z, et al. Remdesivir treatment in hospitalized patients with
- 503 COVID-19: a comparative analysis of in-hospital all-cause mortality in a large multi-center observational cohort. *Clin Infect Dis* 2021.
- 505 25. Gottlieb RL, Vaca CE, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe Covid-
- 506 19 in Outpatients. N Engl J Med 2021.
- 507 26. Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: A clinical-
- therapeutic staging proposal. J Heart Lung Transplant 2020; **39**(5): 405-7.
- 509 27. Mahase E. Covid-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness,
- 510 company reports. *BMJ* 2021; **375**: n2713.
- 511 28. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of
- 512 Covid-19 in Nonhospitalized Patients. N Engl J Med 2021.
- 513 29. W. H. O. REAFC-TWG, Sterne JAC, Murthy S, et al. Association Between Administration of
- 514 Systemic Corticosteroids and Mortality Among Critically III Patients With COVID-19: A Meta-analysis.
- 515 *JAMA* 2020; **324**(13): 1330-41.
- 516 30. Siemieniuk RA, Bartoszko JJ, Ge L, et al. Drug treatments for covid-19: living systematic review
- and network meta-analysis. *BMJ* 2020; **370**: m2980.
- 518 31. Kucirka LM, Lauer SA, Laeyendecker O, Boon D, Lessler J. Variation in False-Negative Rate of
- Reverse Transcriptase Polymerase Chain Reaction-Based SARS-CoV-2 Tests by Time Since Exposure. *Ann*
- 520 Intern Med 2020; **173**(4): 262-7.
- 521 32. Liu STH, Lin HM, Baine I, et al. Convalescent plasma treatment of severe COVID-19: a propensity
- score-matched control study. *Nat Med* 2020; **26**(11): 1708-13.
- 523 33. Klassen SA SJ, Johnson PW, Carter RE, Wiggins CC, Shoham S, Grossman BL, Henderson JP,
- 524 Musser J, Salazar E, Hartman WR Bouvier NM, Liu STH, Pirofski L-A, Baker SE, Helmond N, Wright, RS,
- 525 Fairweather D, Bruno KA, Wang Z, Paneth NS, Casadevall A, Joyner ML. The Effect of convalescent
- 526 plasma therapy on COVID-19 patient mortality: systematic review and meta-analysis. Mayo Clinic
- 527 *Proceedings* 2021; **96**.




Day since COVID-19 diagnosis	0	1	2	3	4	5	6	7	8	9	10
Cancer patients at risk (n)	1107	1105	1101	1096	1091	1081	1072	1064	1059	1057	1052
Non-Cancer patients at risk (n)	2849	2842	2841	2833	2828	2814	2800	2792	2779	2769	2752
Day since COVID-19 diagnosis		11	12	13	14	15	16	17	18	19	20
Cancer patients at risk (n)		1050	1046	1042	1039	1033	1027	1027	1021	1016	1012
Non-Cancer patients at risk (n)		2747	2734	2726	2718	2706	2697	2695	2688	2682	2673
Day since COVID-19 Diagnosis		21	22	23	24	25	26	27	28	29	30
Cancer patients at risk (n)		1011	1007	1006	1006	1005	1003	1000	1000	999	998
Non-Cancer patients at risk (n)		2668	2661	2653	2649	2646	2643	2641	2635	2630	2628




Abbreviation: COPD=Chronic Obstructive Pulmonary Disease; ALC=Absolute Lymphocyte Count; IL-6=Interleukin 6; OR=Odds Ratio; 95% CI= 95% Confidence Interval.

#### A) Cancer patients (N=557)



## B) Non-Cancer patients (N=1777)



Abbreviation: ALC=Absolute Lymphocyte Count; LRTI=Lower Respiratory Tract infection; COPD=Chronic Obstructive Pulmonary Disease; IL-6=Interleukin 6; OR=Odds Ratio; 95% CI= 95% Confidence Interval.

Note\* The upper bound of 95% confidence interval of the odds ratio is not shown in the figure due to the limit of the maximum bound of X-axis.